Literature DB >> 1036468

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

D L Ahmann, H F Bisel, R T Eagan, J H Edmonson, R G Hahn, M J O'Connell, S Frytak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1036468

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  7 in total

1.  Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Authors:  M Bontenbal; A S Planting; J Verweij; R de Wit; W H Kruit; G Stoter; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 2.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Phase II study with etoposide in previously untreated advanced breast cancer.

Authors:  H E Wander; W Rauschning; D Meyer; W Achterrath; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Chronic oral etoposide in advanced breast cancer.

Authors:  H Palombo; J Estapé; N Viñolas; J J Grau; J M Mañé; M Daniels; B Mellado
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02

Review 7.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.